AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10939175 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 8636540 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy with transient ischemia (group I)
Number of subjects: 313
Study 8636540 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker therapy without transient ischemia (group II)
Number of subjects: 313
Study 1592646 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridural analgesia (PDA) with bupivacaine
Number of subjects: 48
Study 1592646 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia (IVA) with pentazocine
Number of subjects: 48
Study 3913095 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 5% cream
Number of subjects: 51
Study 3913095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30789785 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing detailed process information about conflict resolution in withholding treatment (second opinion, ethics consultation, exploring transfer to another institution)
Number of subjects: 1191
Study 30789785 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1191
Study 30198057 — intervention group
Group type: EXPERIMENTAL
Intervention: Resminostat plus sorafenib (resminostat 400 mg/day on days 1 to 5 every 14 days, sorafenib 800 mg/day for 14 days)
Number of subjects: 179
Study 30198057 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib monotherapy (800 mg/day)
Number of subjects: 179
Study 30198057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (resminostat plus sorafenib)
Number of subjects: 179
Study 30198057 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib monotherapy
Number of subjects: 179
Study 30198057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (resminostat plus sorafenib) among patients with normal-to-high baseline platelet count (≥ 150 × 103/mm3)
Number of subjects: 179
Study 30198057 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib monotherapy among patients with normal-to-high baseline platelet count (≥ 150 × 103/mm3)
Number of subjects: 179
Study 27521970 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone and dexmedetomidine (group OD)
Number of subjects: 84
Study 27521970 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone alone (group O)
Number of subjects: 84
Study 25561816 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and S‐1 combination therapy (recurrent group)
Number of subjects: 0
Study 25561816 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and S‐1 combination therapy (unresectable group)
Number of subjects: 0
Study 25561816 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (recurrent group)
Number of subjects: 0
Study 25561816 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (unresectable group)
Number of subjects: 0
Study 25561816 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 (recurrent group)
Number of subjects: 0
Study 25561816 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 (unresectable group)
Number of subjects: 0
Study 25561816 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenia (recurrent group)
Number of subjects: 0
Study 25561816 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenia (unresectable group)
Number of subjects: 0
Study 22634189 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 19
Study 22634189 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Number of subjects: 19
Study 22634189 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 19
Study 22634189 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein and Maltodextrin
Number of subjects: 19
Study 22634189 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin and Whey protein
Number of subjects: 19
Study 20215710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, 70 mg/dL for secondary prevention)
Number of subjects: 400
Study 20215710 — intervention group
Group type: COMPARATOR
Intervention: Conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007)
Number of subjects: 400
Study 19469273 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (2 mg of estradiol and 0.5 mg of norgestrel)
Number of subjects: 94
Study 19469273 — intervention group
Group type: COMPARATOR
Intervention: Cimicifuga recemosa (refemin)
Number of subjects: 94
Study 15916866 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methadone
Number of subjects: 75
Study 15916866 — intervention group
Group type: COMPARATOR
Intervention: D,L-methadone
Number of subjects: 75
Study 12428068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subnitrate plus metronidazole and amoxicillin (group A)
Number of subjects: 157
Study 12428068 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine and metoclopramide (group B)
Number of subjects: 157
Study 12428068 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy after 3 months for group B non-responders
Number of subjects: 157
Study 12428068 — intervention group
Group type: COMPARATOR
Intervention: Non-eradicated cases (group B)
Number of subjects: 157
Study 10891819 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation
Number of subjects: 0
Study 10891819 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation
Number of subjects: 0
Study 10891819 — intervention group
Group type: COMPARATOR
Intervention: Growth-restricted children
Number of subjects: 0
Study 10891819 — intervention group
Group type: COMPARATOR
Intervention: Non-growth-restricted children
Number of subjects: 0
Study 8880666 — intervention group
Group type: EXPERIMENTAL
Intervention: strengths‐based case management
Number of subjects: 632
Study 8880666 — intervention group
Group type: COMPARATOR
Intervention: substance abuse treatment without case management
Number of subjects: 632
Study 1319109 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 12
Study 1319109 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 ethyl esters
Number of subjects: 12
Study 1319109 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 12
Study 1319109 — intervention group
Group type: COMPARATOR
Intervention: All three diets
Number of subjects: 12
Study 6742383 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 90
Study 6742383 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 90
Study 31525580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruptive clinical decision support (CDS) alerts
Number of subjects: 958
Study 31525580 — intervention group
Group type: COMPARATOR
Intervention: Non-interruptive clinical decision support (CDS) alerts
Number of subjects: 958
Study 29377735 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 300
Study 29377735 — intervention group
Group type: COMPARATOR
Intervention: Traditional Care (TC)
Number of subjects: 300
Study 26898340 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin impregnated collagen sponge (GICS) at gentamicin dose = 6 mg/kg (n = 9)
Number of subjects: 18
Study 26898340 — intervention group
Group type: COMPARATOR
Intervention: Sham operation (n = 9)
Number of subjects: 18
Study 23893101 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (PEERS intervention)
Number of subjects: 58
Study 23893101 — intervention group
Group type: COMPARATOR
Intervention: Waitlist comparison group
Number of subjects: 58
Study 21803927 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to tobacco advertisements at more than four places
Number of subjects: 2782
Study 21803927 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to tobacco advertisements at more than four places among boys
Number of subjects: 2782
Study 21803927 — intervention group
Group type: EXPERIMENTAL
Intervention: High receptivity to tobacco advertising among boys
Number of subjects: 2782
Study 21803927 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exposed to tobacco advertisements)
Number of subjects: 2782
Study 21146673 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO risk allele (A)
Number of subjects: 21674
Study 21146673 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-active women (≤8.8 metabolic equivalent‐h/wk) with FTO risk allele (A/A)
Number of subjects: 21674
Study 21146673 — intervention group
Group type: COMPARATOR
Intervention: More-active women
Number of subjects: 21674
Study 17924889 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous remifentanil infusion
Number of subjects: 46
Study 17924889 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl bolus administration
Number of subjects: 46
Study 15784108 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in daytime symptoms of 1-5 U over baseline
Number of subjects: 983
Study 15784108 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in daytime symptoms of two or more over baseline
Number of subjects: 983
Study 11095542 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP) program delivered via bibliotherapy
Number of subjects: 0
Study 11095542 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study 9024516 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin solution (25 U/ml) with vancomycin (25 mcg/ml) for daily catheter flush (HepVan)
Number of subjects: 83
Study 9024516 — intervention group
Group type: COMPARATOR
Intervention: Heparin solution (25 U/ml) without vancomycin (Hep)
Number of subjects: 83
Study 8333266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 45
Study 8333266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol
Number of subjects: 45
Study 8333266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3101502 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic tear formulations (including hyaluronic acid and chondroitin sulfate)
Number of subjects: 20
Study 3101502 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl alcohol artificial tear
Number of subjects: 20
Study 3101502 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate solution
Number of subjects: 20
Study 3101502 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinyl alcohol or hyaluronic acid solution
Number of subjects: 20
Study 2634104 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session smoking prevention intervention
Number of subjects: 471
Study 31199766 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysentery compound (DC)
Number of subjects: 60
Study 31199766 — intervention group
Group type: COMPARATOR
Intervention: Individualized homeopathy (IH)
Number of subjects: 60
Study 28388661 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher community involvement (volunteer activities, community events, clubs for the elderly)
Number of subjects: 825
Study 28388661 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher community involvement (for older women living with others)
Number of subjects: 825
Study 28388661 — intervention group
Group type: COMPARATOR
Intervention: Individual relationship (friendship, communication with family and friends, hobbies)
Number of subjects: 825
Study 28388661 — intervention group
Group type: COMPARATOR
Intervention: Overall psychological distress
Number of subjects: 825
Study 25633208 — intervention group
Group type: EXPERIMENTAL
Intervention: Small change eating and physical activity intervention (SC) combined with positive affect and self-affirmation (PA/SA) intervention
Number of subjects: 574
Study 25633208 — intervention group
Group type: COMPARATOR
Intervention: Small change eating and physical activity intervention (SC) alone
Number of subjects: 574
Study 22828963 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured supervised group exercises, group lectures, individual counselling and telephone follow‐up
Number of subjects: 150
Study 22828963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 21257787 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered air (using portable air filters)
Number of subjects: 45
Study 19193426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileocolonic neobladder
Number of subjects: 71
Study 19193426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal neobladder
Number of subjects: 71
Study 16389165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (5 mg/kg)
Number of subjects: 15
Study 16389165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (7.5 mg/kg)
Number of subjects: 15
Study 16389165 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study 15194383 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin administration
Number of subjects: 21
Study 15194383 — intervention group
Group type: COMPARATOR
Intervention: Control (no somatostatin)
Number of subjects: 21
Study 12774336 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 42
Study 12774336 — intervention group
Group type: COMPARATOR
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 42
Study 12774336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LNF and ONF
Number of subjects: 42
Study 9059166 — intervention group
Group type: EXPERIMENTAL
Intervention: Preci-Jet 50 transjector for growth hormone delivery
Number of subjects: 0
Study 9059166 — intervention group
Group type: COMPARATOR
Intervention: Pen injection system for growth hormone delivery
Number of subjects: 0
Study 8377957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methotrexate, 15 mg weekly
Number of subjects: 11
Study 8377957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2439800 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (20 mg)
Number of subjects: 5
Study 2439800 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 5
Study 2439800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 2439800 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 5
Study 2439800 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg)
Number of subjects: 5
Study 28693638 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a community counselling service (quitline, text-based program, web-based program)
Number of subjects: 1295
Study 28693638 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1295
Study 27524403 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual pain treatment for eight weeks
Number of subjects: 352
Study 27524403 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 352
Study 24554388 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of 50‐60 min of aerobic exercise (HIGH; n = 101)
Number of subjects: 301
Study 24554388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose of 50‐60 min of aerobic and resistance exercise (COMB; n = 104)
Number of subjects: 301
Study 24554388 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of 25‐30 min of aerobic exercise (STAN; n = 96)
Number of subjects: 301
Study 23301468 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + medication (electroacupuncture at Baihui, Yintang, Sishencong, Taichong, Sanyinjiao) with oral administration of madopar and fluoxetine
Number of subjects: 60
Study 23301468 — intervention group
Group type: COMPARATOR
Intervention: Medication (oral administration of madopar and fluoxetine)
Number of subjects: 60
Study 20522567 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of lidocaine and bupivacaine
Number of subjects: 19
Study 20522567 — intervention group
Group type: COMPARATOR
Intervention: Control group from INVEST trial
Number of subjects: 19
Study 18430433 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterexample retrieval in Experiment 1
Number of subjects: 0
Study 18430433 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional reasoning task in Experiment 2
Number of subjects: 0
Study 18430433 — intervention group
Group type: EXPERIMENTAL
Intervention: Modus ponens inference in Experiment 2
Number of subjects: 0
Study 16544441 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan
Number of subjects: 0
Study 16544441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12967798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with intraoperative perfluoro-n-octane (PFO)
Number of subjects: 555
Study 11075315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 30 mg
Number of subjects: 15
Study 11075315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9163278 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 1 mg/kg
Number of subjects: 54
Study 9163278 — intervention group
Group type: COMPARATOR
Intervention: Ketamine racemate 2 mg/kg
Number of subjects: 54
Study 9163278 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 0.5 mg/kg
Number of subjects: 54
Study 9163278 — intervention group
Group type: COMPARATOR
Intervention: Ketamine racemate 1 mg/kg
Number of subjects: 54
Study 9163278 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 2 mg/kg
Number of subjects: 54
Study 9163278 — intervention group
Group type: COMPARATOR
Intervention: Ketamine racemate 4 mg/kg
Number of subjects: 54
Study 9163278 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 1 mg/kg with midazolam
Number of subjects: 54
Study 9163278 — intervention group
Group type: COMPARATOR
Intervention: Ketamine racemate 2 mg/kg with midazolam
Number of subjects: 54
Study 8369784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-triple combination of isoniazid (750 mg), rifampicin (600 mg), and pyrazinamide (2,250 mg)
Number of subjects: 6
Study 8369784 — intervention group
Group type: COMPARATOR
Intervention: Individual administration of isoniazid (750 mg), rifampicin (600 mg), and pyrazinamide (2,250 mg)
Number of subjects: 6
Study 3526102 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 16
Study 3526102 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 16
Study 31063574 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg (n=1208)
Number of subjects: 2422
Study 31063574 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=1214)
Number of subjects: 2422
Study 28750737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ppm NO inhalation
Number of subjects: 12
Study 28750737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26837983 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% phenytoin mouthwash
Number of subjects: 16
Study 26837983 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16
Study 23530474 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI followed by Postconditioning (PostC)
Number of subjects: 68
Study 23530474 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 68
Study 23530474 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 68
Study 21470289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general anaesthesia and epidural analgesia (Group 2)
Number of subjects: 25
Study 21470289 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (Group 1)
Number of subjects: 25
Study 18640991 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1 infusion (1.0-2.5 ng kg(‐1) min(‐1))
Number of subjects: 9
Study 18640991 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 9
Study 18640991 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1 infusion
Number of subjects: 9
Study 16801464 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy pretreatment
Number of subjects: 215
Study 16801464 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI (Control)
Number of subjects: 215
Study 14507836 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 2 transfer
Number of subjects: 193
Study 14507836 — intervention group
Group type: COMPARATOR
Intervention: Day 5 transfer
Number of subjects: 193
Study 11028255 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic-feedback training exercise (AFTE)
Number of subjects: 33
Study 11028255 — intervention group
Group type: COMPARATOR
Intervention: Promethazine (25 mg)
Number of subjects: 33
Study 11028255 — intervention group
Group type: COMPARATOR
Intervention: Promethazine (50 mg)
Number of subjects: 33
Study 11028255 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 33
Study 8899773 — intervention group
Group type: EXPERIMENTAL
Intervention: Free bone graft (group A)
Number of subjects: 20
Study 8899773 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoperiosteal trapdoor (group B)
Number of subjects: 20
Study 1672059 — intervention group
Group type: EXPERIMENTAL
Intervention: isostable group (isoflurane maintained at 1.25%)
Number of subjects: 36
Study 1672059 — intervention group
Group type: EXPERIMENTAL
Intervention: isostop group (isoflurane discontinued before neostigmine administration)
Number of subjects: 36
Study 1672059 — intervention group
Group type: COMPARATOR
Intervention: control group (fentanyl/N2O only)
Number of subjects: 36
Study 6839001 — intervention group
Group type: EXPERIMENTAL
Intervention: enteric‐coated ASA (ecASA)
Number of subjects: 12
Study 6839001 — intervention group
Group type: EXPERIMENTAL
Intervention: compressed ASA tablets (cASA)
Number of subjects: 12
Study 6839001 — intervention group
Group type: COMPARATOR
Intervention: sodium salicylate (578 mg)
Number of subjects: 12
Study 30639991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBTp plus treatment as usual (TAU)
Number of subjects: 48
Study 30639991 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation group (PsyEdI) plus TAU
Number of subjects: 48
Study 30639991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBTp
Number of subjects: 48
Study 30480729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 150 mg every 4 weeks (n=28)
Number of subjects: 125